PLUR - חוב כולל להון Pluri
The market valuation trend for Pluri Inc. (PLUR) based on the total debt-to-equity ratio is 0.00. Pluri Inc. (PLUR) is facing a revenue shortfall due to the slow validation of its 3D cultivation systems' effectiveness, which threatens a financial gap. The business relies on creating scalable cell platforms for therapy and nutrition while struggling with a high burn rate and a history of failed tests.
%20-%20%D7%99%D7%97%D7%A1%20%D7%9B%D7%9C%D7%9C%20%D7%94%D7%97%D7%95%D7%91%D7%95%D7%AA%20%D7%9C%D7%9E%D7%A7%D7%95%D7%A8%D7%95%D7%AA%20%D7%A2%D7%A6%D7%9E%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_PLUR_-_Pluri-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "PLUR (Pluri) היסטוריית חוב כולל להון מ-28.04.2023 עד 29.10.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Pluri Inc.
For biotech leader Pluri Inc. (PLUR), with its capital-intensive R&D projects in regenerative medicine, controlling the debt load is a key factor for stability. Analyzing the balance between debt and equity, we see a current value of 0.00, which reflects the proportion of total liabilities relative to net assets, determining the risk of liquidity shortages for interest payments and influencing the final fair value of the business.